Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
04 2019
Historique:
received: 21 02 2018
accepted: 11 03 2018
pubmed: 14 4 2018
medline: 21 4 2020
entrez: 14 4 2018
Statut: ppublish

Résumé

Allogeneic haematopoietic cell transplantation (HCT) is often associated with poor oral intake due to painful mucositis and gastrointestinal sequalae that occur following a preparative regimen of intensive chemotherapy and/or total body radiation. Although attractive to assume that optimal nutrition improves HCT outcomes, there are limited data to support this. It is also unclear whether artificial nutrition support should be provided as enteral tube feeding or parenteral nutrition (PN). We analysed day-100 non-relapse mortality (NRM), incidence of acute graft-versus-host disease (GvHD), acute gastrointestinal GvHD, 5-year survival and GvHD-free/relapse-free survival (GRFS) according to both route and adequacy of nutritional intake prior to neutrophil engraftment, together with other known prognostic factors, in a retrospective cohort of 484 patients who underwent allogeneic HCT for haematologic malignancy between 2000 and 2014. Multivariate analyses showed increased NRM with inadequate nutrition (hazard ratio (HR) 4.1; 95% confidence interval (CI) 2.2-7.2) and adequate PN (HR 2.9; 95% CI 1.6-5.4) compared to adequate enteral nutrition (EN) both P < .001. There were increased incidences of gastrointestinal GvHD of any stage and all GvHD ≥ grade 2 in patients who received PN (odds ratio (OR) 2.0; 95% CI 1.2-3.3; P = .006, and OR 1.8; 95% CI 1.1-3.0; P = .018, respectively), compared to adequate EN. Patients who received adequate PN and inadequate nutrition also had reduced probabilities of survival and GRFS at 5 years. Adequate EN during the early transplantation course is associated with reduced NRM, improved survival and GRFS at 5 years. Furthermore, adequate EN is associated with lower incidence of overall and gut acute GvHD than PN, perhaps because of its ability to maintain mucosal integrity, modulate the immune response to intensive chemo/radiotherapy and support the gastrointestinal tract environment, including gut microflora.

Sections du résumé

BACKGROUND
Allogeneic haematopoietic cell transplantation (HCT) is often associated with poor oral intake due to painful mucositis and gastrointestinal sequalae that occur following a preparative regimen of intensive chemotherapy and/or total body radiation. Although attractive to assume that optimal nutrition improves HCT outcomes, there are limited data to support this. It is also unclear whether artificial nutrition support should be provided as enteral tube feeding or parenteral nutrition (PN).
METHODS
We analysed day-100 non-relapse mortality (NRM), incidence of acute graft-versus-host disease (GvHD), acute gastrointestinal GvHD, 5-year survival and GvHD-free/relapse-free survival (GRFS) according to both route and adequacy of nutritional intake prior to neutrophil engraftment, together with other known prognostic factors, in a retrospective cohort of 484 patients who underwent allogeneic HCT for haematologic malignancy between 2000 and 2014.
RESULTS
Multivariate analyses showed increased NRM with inadequate nutrition (hazard ratio (HR) 4.1; 95% confidence interval (CI) 2.2-7.2) and adequate PN (HR 2.9; 95% CI 1.6-5.4) compared to adequate enteral nutrition (EN) both P < .001. There were increased incidences of gastrointestinal GvHD of any stage and all GvHD ≥ grade 2 in patients who received PN (odds ratio (OR) 2.0; 95% CI 1.2-3.3; P = .006, and OR 1.8; 95% CI 1.1-3.0; P = .018, respectively), compared to adequate EN. Patients who received adequate PN and inadequate nutrition also had reduced probabilities of survival and GRFS at 5 years.
CONCLUSION
Adequate EN during the early transplantation course is associated with reduced NRM, improved survival and GRFS at 5 years. Furthermore, adequate EN is associated with lower incidence of overall and gut acute GvHD than PN, perhaps because of its ability to maintain mucosal integrity, modulate the immune response to intensive chemo/radiotherapy and support the gastrointestinal tract environment, including gut microflora.

Identifiants

pubmed: 29650256
pii: S0261-5614(18)30120-1
doi: 10.1016/j.clnu.2018.03.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-744

Subventions

Organisme : Department of Health
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Auteurs

Julie Beckerson (J)

Nutrition and Dietetics, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address: julie.beckerson@nhs.net.

Richard M Szydlo (RM)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Mary Hickson (M)

Institute of Health and Community, Plymouth University, Devon, UK.

Catriona E Mactier (CE)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Andrew J Innes (AJ)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Ian H Gabriel (IH)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Renuka Palanicawandar (R)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Edward J Kanfer (EJ)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Donald H Macdonald (DH)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Dragana Milojkovic (D)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Amin Rahemtulla (A)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Aristeidis Chaidos (A)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Anastasios Karadimitris (A)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Eduardo Olavarria (E)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Jane F Apperley (JF)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Jiri Pavlu (J)

Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH